GoodRx Holdings, Inc. GDRX Prescription transactions revenue — Selling expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingExpense.
The official record: GoodRx Holdings, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense?
- GoodRx Holdings, Inc. (GDRX) reported prescription transactions revenue — selling expense of $2.8M in Q4 2025.
- How has GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense changed year-over-year?
- GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense decreased by 2.6% year-over-year, from $2.88M to $2.8M.
- What does prescription transactions revenue — selling expense mean?
- This metric captures the direct costs associated with selling activities specifically attributable to the prescription transactions segment, such as commissions or direct sales force compensation. It provides insight into the variable cost structure required to maintain and expand the transaction-based revenue stream. Monitoring this expense helps assess the operational efficiency and the cost-to-serve ratio for the company's core prescription business.